{"ticker": {"uuid": "cba9d64e-eba8-4722-8bbf-6786a467b60c", "symbol": "BCAX", "name": "Bicara Therapeutics Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Bicara Therapeutics (BCAX) Corporate presentation Summary", "summary": "Bicara Therapeutics (BCAX) presented a corporate summary focusing on its lead candidate, ficerafusp alfa (FICERA), a bifunctional antibody targeting EGFR and TGF-\u03b2 for HPV-negative head and neck squamous cell carcinoma (HNSCC). The company highlighted FICERA's potential for block", "url": "https://quartr.com/events/bicara-therapeutics-bcax-corporate-presentation_FsEGAndb", "source_name": "Quartr", "published_at": "2026-07-20T20:09:14", "published_display": "20 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Study update Summary", "summary": "Bicara Therapeutics (BCAX) released a study update on May 22, 2026, detailing the efficacy and safety of Ficera (ficerafusp alfa) plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The phase 1/1b expansion cohorts sho", "url": "https://quartr.com/events/bicara-therapeutics-bcax-study-update_FsEGO6cF", "source_name": "Quartr", "published_at": "2026-07-20T11:09:14", "published_display": "20 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Proxy filing Summary", "summary": "Bicara Therapeutics (BCAX) has scheduled its Annual Meeting for June 9, 2026, with voting concluding on June 8, 2026. Key agenda items include the election of Christopher Bowden, M.D., and Carolyn Ng, Ph.D., as Class II directors, and the ratification of KPMG LLP as the independe", "url": "https://quartr.com/events/bicara-therapeutics-inc-bcax-proxy-filing_FsEGO3zK", "source_name": "Quartr", "published_at": "2026-07-19T16:10:52", "published_display": "19 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Q1 2026 earnings summary", "summary": "Bicara Therapeutics (BCAX) reported its Q1 2026 earnings, highlighting progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, with enrollment expected by year-end 2026 and interim analysis in mid-2027. The company's cash reserves increased to $539.8M following a $161.8M ", "url": "https://quartr.com/events/bicara-therapeutics-inc-bcax-q1-2026_FsEGAntG", "source_name": "Quartr", "published_at": "2026-07-18T21:09:59", "published_display": "18 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com", "summary": "This article reports on a Form 4 filing for Bicara Therapeutics Inc. on July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article provides only this headline information and includes no further details abou", "url": "https://ng.investing.com/news/stock-market-news/form-4-bicara-therapeutics-inc-for-14-july-93CH-2599532", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T02:11:18", "published_display": "16 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock", "summary": "Bicara Therapeutics CEO Claire Mazumdar sold approximately $284,198 worth of common stock on July 10, 2026, through a pre-arranged trading plan. Concurrently, she acquired 10,000 shares by exercising stock options for $37,898. The transactions follow a 177% surge in Bicara's stoc", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-ceo-claire-mazumdar-disposes-of-284k-in-stock-93CH-4791684", "source_name": "Investing.com", "published_at": "2026-07-14T21:42:28", "published_display": "14 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan", "summary": "Bicara Therapeutics Inc. CEO Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share and subsequently sold all 10,000 shares in open-market transactions on July 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan ado", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-e9478fccf3ef.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:42:28", "published_display": "14 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX)", "summary": "Bicara Therapeutics recently released encouraging extended follow-up data for its ficerafusp alfa with pembrolizumab in HPV-negative head and neck squamous cell carcinoma. This positive clinical news follows a sale of company stock by CFO Hyep Ivan, creating mixed signals for inv", "url": "https://www.sahmcapital.com/news/content/extended-trial-data-and-insider-sale-could-be-a-game-changer-for-bicara-therapeutics-bcax-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-12T14:10:52", "published_display": "12 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "The article provides the enterprise value to revenue forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It specifies that the market is closed and no trades were made, listing this financial metric within the company's detailed profile on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T14:09:34", "published_display": "12 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan", "summary": "Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options for 18,750 shares and subsequently sold 28,750 shares of common stock between July 8-9, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices ranging f", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-ac88f33c89df.html", "source_name": "Stock Titan", "published_at": "2026-07-11T13:11:41", "published_display": "11 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Bicara Therapeutics Inc. Insider Trading Activity", "summary": "Bicara Therapeutics Inc.'s Chief Financial Officer, Ivan Hyep, reported exercising stock options for 12,500 shares and selling 28,000 common shares on July 8, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved selling shares at weighted ave", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-e669463cf088.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:09:34", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com", "summary": "This article announces the filing of Form 144 for Bicara Therapeutics Inc. on July 10. Such filings indicate an insider's intent to sell restricted or controlled securities, making this relevant for investors watching company insider activity. The article also mentions the stock ", "url": "https://ng.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-10-july-93CH-2595654", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:28:00", "published_display": "10 Jul 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Bicara Therapeutics Inc. on July 10th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in the company's stock. The article mentions the compa", "url": "https://za.investing.com/news/stock-market-news/form-4-bicara-therapeutics-inc-for-10-july-93CH-4364894", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T22:20:00", "published_display": "10 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "This article focuses on the enterprise value to EBIT forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It presents a specific financial metric for the company, indicating data relevant to investors and financial analysts. The rest of the content includes standard navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T21:10:47", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara therapeutics president & COO sells $833k in stock", "summary": "Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, sold approximately $833,129 worth of stock on July 8 and 9, 2026, under a pre-arranged trading plan. This followed an exercise of stock options worth $71,058. The sales occurred while the stock was near its 52-week high", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-president--coo-sells-833k-in-stock-93CH-4786793", "source_name": "Investing.com", "published_at": "2026-07-10T20:39:13", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics CFO Hyep Ivan sells $807k in stock", "summary": "Bicara Therapeutics CFO Hyep Ivan sold approximately $807,671 worth of common stock on July 8, 2026, with shares trading near their 52-week high after a significant 199% return. Concurrently, Mr. Hyep acquired 12,500 shares through stock option exercise as part of a Rule 10b5-1 t", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-cfo-hyep-ivan-sells-807k-in-stock-93CH-4786792", "source_name": "Investing.com", "published_at": "2026-07-10T20:39:13", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara therapeutics president & COO sells $833k in stock By Investing.com", "summary": "Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ:BCAX), sold approximately $833,129 worth of stock following the exercise of stock options. These transactions, executed under a Rule 10b5-1 trading plan, occurred as the stock traded near its 52-week high, despi", "url": "https://ca.investing.com/news/stock-market-news/bicara-therapeutics-president--coo-sells-833k-in-stock-93CH-4729745", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:10:48", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing", "summary": "An insider at Bicara Therapeutics (NASDAQ: BCAX) recently sold shares amounting to $833,129, as disclosed in a filing with the SEC. The sale was published on July 10, 2026, at 04:20 pm EDT. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bi", "url": "https://www.marketscreener.com/news/bicara-therapeutics-insider-sold-shares-worth-833-129-according-to-a-recent-sec-filing-ce7f5edfdb8cff26", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T16:20:00", "published_display": "10 Jul 2026 16:20", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) CFO sells 28K shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSWVrUGpxVklJNV84ay14Q2xGSk9aRkpvSldlRjV0MXN6eVJ3Q1JUcjM3Y0xFY1BydXZ5R0syQUo1amtXUWZtbXZoazFyZG9ncHVMcFM2bU5PVWxrNE8yWS1HaVkwSDRhSXdFMDdzWXBqc3EwbHlBWTFDOW9mREZDRWZ2ZXo3YXY2cWhoZlRLdEhqbktobnlDRm96S2NiZXNmQ1h4YkJKamxkREVlSFVTT1lzNGxkcVJL?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "This article provides financial information for Bicara Therapeutics Inc. (NASDAQ: BCAX), specifically focusing on its price-to-book forward ratio. It's presented within the context of TradingView's financial data platform, indicating key financial metrics for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T09:11:07", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com", "summary": "Investing.com reported on a Form 144 filing by Bicara Therapeutics Inc. for July 8th, indicating an insider transaction or an intent to sell restricted securities. The article, primarily a brief announcement, also includes current stock market data and a disclaimer about trading ", "url": "https://ng.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-8-july-93CH-2591645", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:11:07", "published_display": "08 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX)", "summary": "BCAX has filed a Form 144 notice disclosing the planned sale of 28,750 shares. This includes 10,000 shares from an option exercise on May 12, 2024, and 18,750 shares from another exercise on July 8, 2026. The filing also reports two recent sales by Ryan Cohlhepp: 12,500 shares fo", "url": "https://www.stocktitan.net/sec-filings/BCAX/144-bicara-therapeutics-inc-sec-filing-3d32d5f377a4.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:15", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted", "summary": "An affiliate of Bicara Therapeutics Inc. (BCAX) has filed a Rule 144 notice, indicating proposed sales of 28,000 shares valued at $847,000.00. The filing also detailed two past sales of 9,200 shares each on April 21, 2026, and May 21, 2026, with proceeds of $211,613.80 and $187,8", "url": "https://www.stocktitan.net/sec-filings/BCAX/144-bicara-therapeutics-inc-sec-filing-3d017daa744b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:14", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics\u00a0Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bicara-therapeutics-announces-inducement-grants-123000363.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:30:00+00:00", "published_display": "02 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/645262f3-5acb-3572-a29f-6d292e178204/what-does-the-bicara.html", "source_name": "Motley Fool", "published_at": "2026-06-13T05:21:24+00:00", "published_display": "13 Jun 2026 05:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara (BCAX) Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/b4a29f0b-e79a-3c2f-b18f-5f8e1e14e56e/bicara-%28bcax%29-q4-2025.html", "source_name": "Motley Fool", "published_at": "2026-06-01T16:13:09+00:00", "published_display": "01 Jun 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer", "summary": "", "url": "https://finance.yahoo.com/m/caf6c987-59dc-3d24-bb50-760d13bee685/bicara-therapeutics-asco-data.html", "source_name": "MarketBeat", "published_at": "2026-05-22T15:09:40+00:00", "published_display": "22 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPVDNPN0xESUVqR1Y3bkYxaFJHS3dvaV82aWREUEVYam5MZHpaSFBtbFl2dUt6M1lSd3lwcmZ4YnZsc1hRNjFtQVdfVzEyVk4zeVVtX0JEYWREdFdIZGhrQUgza0NQSHlVWFRWQS1sN0Zya0N4R3VTYXJmLW9Ba25Nd21CVTRTMHdwXzlQSHRSYnZyRlFTNmlXSkVhNnlrOVNzMVZ5ZlJwVQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back", "summary": "", "url": "https://finance.yahoo.com/m/57f8007a-837d-3071-9902-8e6149055817/alumis-stock-is-up-over-300%25..html", "source_name": "Motley Fool", "published_at": "2026-05-15T22:56:41+00:00", "published_display": "15 May 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbk14TUdzc3ZZQWtndk44c014UnFlcGJBeHBuUEVqUndvOVloSkkxb1hOQXdrSWZSdGN6MXhzYkYwTFVXVDhZSFNLczVYblBzSjlFNGNNdFZ2Rk9ZV0dHX3NRT3N5YkZ2aFFOSDhKWk10M3EzdDhYd3daVVBoZHhpOVI5RDRLdUVfWk90NFp1MDAwZWE1MEYw?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data", "summary": "", "url": "https://finance.yahoo.com/m/5a253d10-428f-3931-b525-b06d05c87508/bicara-therapeutics-touts.html", "source_name": "MarketBeat", "published_at": "2026-05-14T21:09:08+00:00", "published_display": "14 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New Bicara commercial chief lands option on 282,240 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbVZrVHc3VkhGaUh0ckIzZnZ0QTdaQVU2UERQNGVaX2l6aDZDdWlDVzJMcGw3bmt3aUtLbUdpZzhsRzA3R2t1SllJcW1LYWNuRzZKQjgtT3l2a3NmX0VONzNMZVVjbkRValJMTjVyUHlVNnlDWU5hVVV1LUp1Zml3eUhXcnR4TFpCWkhRZW0taHVDTHhJLTlIYUw0ZlV6Yno4WVphVjlrMEs2ankyblZ1NlZGUVpUcXBPMWU5UVZubw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Bicara Therapeutics Q1 2026 sees stock dip after earnings miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQc21RYUE0eVJOZlNHZllBcjhkMmYtMEpGVmF4S0ZGRGNGTXNrZHpLN3diSVVkLXhQSFJ2Rm40RDJEWUkzR1JGOVJmZk9FUmFvYmlPalBfT2pBd0JUcXRxazhqVGUxS3E0NkdpMzdlZkJmOUNRLWYxSHlCTVE3UXF3NHNuRmZaVjRHYi04SkJCRHAxNjhfR3VCRnlwY0tOV3d3ZWFLUFFqamJJellYTW5kcnQzblg5WW1VTVk3MzIxYzdEN292UDFQT0p2OEs2eWJ1cGNKNDRfR1BtV00?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bicara Therapeutics CFO Hyep sells $211k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNc1NRcDdCX203ZzdfcHZNdTZDbThIM1NmMFpmb2haSTlrRUV5ZDljaGhTT1VxaERFX1pxa09uUHQ1VThLbE9yR1NES25SNnRqX3pRMy1naWlqS19sOEhNNk9ERmtyVWV3cmNwbHJibXFidWtGdHE3TEUyOUlmaDlsbC1pM3UybUNFcFpYaWZQM0lvVkhrN2tzUmhRVS1LSzgwVExyekJ0N3VkNDBxRjVxRW5Ddw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQNDYtQjByZDFJaDlGMlk4bXdmWjBjajdGOXJxcE9hUFRadnVpVmVDSENfRzZFTERwbEsxem9pbEkxR3JLeUxTeFVldlpkUmo0UVdiZ0VkV0ExeXR2Q2FaU2RESjh1OV9mQ1AzcHhyTDJ4bENXMkppd2h5TXNpbzJ6WUswTkpQa1dRVkxwZ0dteHN5MjBnSGZzcHZBN3FlYTlJbnhnQkp4Zw?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQ2lVTENhT2o5bEV3U212MFpUc09VeWFNQmVPRldmakFPS1VyN0tCQ2MxZUQ5dkRfdVdUTUdqWG9QNzNyQ3ZoNGtidFFsTjQybWstUFl4bERWMVlMMkFUcFJsdmJyUWxFank5a2ZGNTZNdWJZR0hSNko4SmQ2UVYtaEVoTmxRWXV6M2V4MzFkd0wySDljLTZDU1VaLS1oekpJRXU1UW1VRWctd21yN3BZZVFTaw?oc=5", "source_name": "qz.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPNEdacW1mbHdoNnFnQkJlVVB5dE5wME41XzRqeWFVLXRkWDluMVpWZTZkbEotUW85U3I5anRZbUNpWUUzeXpVb3ZDMUJKOU1wYVZ2d2xncERLM2JrV1RvTDNNWmt1YmRLNDRTaDB6RWlHWUdMUWotOXpWYWJnbFlIRG9QRjh6ckpnWDlQczVB?oc=5", "source_name": "Market source", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara raises $172.5M to back planned ficerafusp alfa U.S. launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZUszUEJEV0xGMEQ3bm9QZWN0OUZPcXpUOUNuQXowQS15OGJLTjdBTTA4S2JRRTZwRzltbkZkaFdDYUZLN2JHckFXdF9nV1VIQy1nQkhRZVhGME5MOVd0cDZNUVZyZ08zY3V1WW9NWS14bW93dEMxMF8tQVRwMG1ZNVZuMVBOaWszZHlRZ1MtUG1CdzBiWWVxZXFSSVAyQzZ3NmJtT3RRQkE2a2p0OERMSFVMNHNhR25Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxOSEpBSHhvRjE4T3lLdGlZQzdQZ1NxMkcxSTB4T2tPb2pWdDBpUGc2azBRQmhJc2pFYkFsRlhmcXIyVWlubTNPNmE5X0dyNnVNbkhSMjc1YktBS2pqRjhQblViaXN0Xy1WTzVpV2xCbXFKWlZxYm5rclZ6Q0ZpT1JfSkJNLWl4Z2NWZlRaNkVXeWtsN3ZJM2NOQjA2WFRLdHJKVUo5T1dRdVVCQ0hBbGNuZzVLclpkNTRqM1VZMXZvTWtGQ20xNjY1ZFZnOTZZR0RNc0hZdXdFUlMtUnQwZ0h5dWx1YmNFckxwYXVnNFZKWnUtOG5zandKQ0QyM0VlMFltcFVOc0NhVjQ1YUhV?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug push: Bicara seeks $150M stock sale for launch prep", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWXZGekxrSlRBTXZJa1o5V3dnSTNaVUQ0aHdMclBXTDFwYVpsV2Y0Si01RFBmUzdYSnJvM2NEN2dFWFk4M3QzVzNRUFozaWVYSkVfenNTbi1TMDllTWlvWG1OVDZYNzlwS3k0QlZvQTRUOHE4bW5VZkRPbF9lbWlyMmcwT3NjRGJRSW9Tblo0dzhhV25fMnNrb3N1N0tRTDR2OUF2VFhsUWdEc1A5YmszdXJKNE15aHZzbGxz?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Bicara Therapeutics (BCAX) Corporate presentation Summary", "summary": "Bicara Therapeutics (BCAX) presented a corporate summary focusing on its lead candidate, ficerafusp alfa (FICERA), a bifunctional antibody targeting EGFR and TGF-\u03b2 for HPV-negative head and neck squamous cell carcinoma (HNSCC). The company highlighted FICERA's potential for block", "url": "https://quartr.com/events/bicara-therapeutics-bcax-corporate-presentation_FsEGAndb", "source_name": "Quartr", "published_at": "2026-07-20T20:09:14", "published_display": "20 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Study update Summary", "summary": "Bicara Therapeutics (BCAX) released a study update on May 22, 2026, detailing the efficacy and safety of Ficera (ficerafusp alfa) plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The phase 1/1b expansion cohorts sho", "url": "https://quartr.com/events/bicara-therapeutics-bcax-study-update_FsEGO6cF", "source_name": "Quartr", "published_at": "2026-07-20T11:09:14", "published_display": "20 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Proxy filing Summary", "summary": "Bicara Therapeutics (BCAX) has scheduled its Annual Meeting for June 9, 2026, with voting concluding on June 8, 2026. Key agenda items include the election of Christopher Bowden, M.D., and Carolyn Ng, Ph.D., as Class II directors, and the ratification of KPMG LLP as the independe", "url": "https://quartr.com/events/bicara-therapeutics-inc-bcax-proxy-filing_FsEGO3zK", "source_name": "Quartr", "published_at": "2026-07-19T16:10:52", "published_display": "19 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) Q1 2026 earnings summary", "summary": "Bicara Therapeutics (BCAX) reported its Q1 2026 earnings, highlighting progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, with enrollment expected by year-end 2026 and interim analysis in mid-2027. The company's cash reserves increased to $539.8M following a $161.8M ", "url": "https://quartr.com/events/bicara-therapeutics-inc-bcax-q1-2026_FsEGAntG", "source_name": "Quartr", "published_at": "2026-07-18T21:09:59", "published_display": "18 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com", "summary": "This article reports on a Form 4 filing for Bicara Therapeutics Inc. on July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article provides only this headline information and includes no further details abou", "url": "https://ng.investing.com/news/stock-market-news/form-4-bicara-therapeutics-inc-for-14-july-93CH-2599532", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T02:11:18", "published_display": "16 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock", "summary": "Bicara Therapeutics CEO Claire Mazumdar sold approximately $284,198 worth of common stock on July 10, 2026, through a pre-arranged trading plan. Concurrently, she acquired 10,000 shares by exercising stock options for $37,898. The transactions follow a 177% surge in Bicara's stoc", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-ceo-claire-mazumdar-disposes-of-284k-in-stock-93CH-4791684", "source_name": "Investing.com", "published_at": "2026-07-14T21:42:28", "published_display": "14 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan", "summary": "Bicara Therapeutics Inc. CEO Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share and subsequently sold all 10,000 shares in open-market transactions on July 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan ado", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-e9478fccf3ef.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:42:28", "published_display": "14 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Extended Trial Data And Insider Sale Could Be A Game Changer For Bicara Therapeutics (BCAX)", "summary": "Bicara Therapeutics recently released encouraging extended follow-up data for its ficerafusp alfa with pembrolizumab in HPV-negative head and neck squamous cell carcinoma. This positive clinical news follows a sale of company stock by CFO Hyep Ivan, creating mixed signals for inv", "url": "https://www.sahmcapital.com/news/content/extended-trial-data-and-insider-sale-could-be-a-game-changer-for-bicara-therapeutics-bcax-2026-07-12", "source_name": "Sahm", "published_at": "2026-07-12T14:10:52", "published_display": "12 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "The article provides the enterprise value to revenue forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It specifies that the market is closed and no trades were made, listing this financial metric within the company's detailed profile on TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T14:09:34", "published_display": "12 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan", "summary": "Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options for 18,750 shares and subsequently sold 28,750 shares of common stock between July 8-9, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices ranging f", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-ac88f33c89df.html", "source_name": "Stock Titan", "published_at": "2026-07-11T13:11:41", "published_display": "11 Jul 2026 13:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Bicara Therapeutics Inc. Insider Trading Activity", "summary": "Bicara Therapeutics Inc.'s Chief Financial Officer, Ivan Hyep, reported exercising stock options for 12,500 shares and selling 28,000 common shares on July 8, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, involved selling shares at weighted ave", "url": "https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-e669463cf088.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:09:34", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Bicara Therapeutics Inc. For: 10 July By Investing.com", "summary": "This article announces the filing of Form 144 for Bicara Therapeutics Inc. on July 10. Such filings indicate an insider's intent to sell restricted or controlled securities, making this relevant for investors watching company insider activity. The article also mentions the stock ", "url": "https://ng.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-10-july-93CH-2595654", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:28:00", "published_display": "10 Jul 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Bicara Therapeutics Inc For: 10 July By Investing.com", "summary": "This article reports on the filing of Form 4 for Bicara Therapeutics Inc. on July 10th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in the company's stock. The article mentions the compa", "url": "https://za.investing.com/news/stock-market-news/form-4-bicara-therapeutics-inc-for-10-july-93CH-4364894", "source_name": "Investing.com South Africa", "published_at": "2026-07-10T22:20:00", "published_display": "10 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "This article focuses on the enterprise value to EBIT forward for Bicara Therapeutics Inc. (NASDAQ: BCAX). It presents a specific financial metric for the company, indicating data relevant to investors and financial analysts. The rest of the content includes standard navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T21:10:47", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara therapeutics president & COO sells $833k in stock", "summary": "Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, sold approximately $833,129 worth of stock on July 8 and 9, 2026, under a pre-arranged trading plan. This followed an exercise of stock options worth $71,058. The sales occurred while the stock was near its 52-week high", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-president--coo-sells-833k-in-stock-93CH-4786793", "source_name": "Investing.com", "published_at": "2026-07-10T20:39:13", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics CFO Hyep Ivan sells $807k in stock", "summary": "Bicara Therapeutics CFO Hyep Ivan sold approximately $807,671 worth of common stock on July 8, 2026, with shares trading near their 52-week high after a significant 199% return. Concurrently, Mr. Hyep acquired 12,500 shares through stock option exercise as part of a Rule 10b5-1 t", "url": "https://www.investing.com/news/insider-trading-news/bicara-therapeutics-cfo-hyep-ivan-sells-807k-in-stock-93CH-4786792", "source_name": "Investing.com", "published_at": "2026-07-10T20:39:13", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara therapeutics president & COO sells $833k in stock By Investing.com", "summary": "Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ:BCAX), sold approximately $833,129 worth of stock following the exercise of stock options. These transactions, executed under a Rule 10b5-1 trading plan, occurred as the stock traded near its 52-week high, despi", "url": "https://ca.investing.com/news/stock-market-news/bicara-therapeutics-president--coo-sells-833k-in-stock-93CH-4729745", "source_name": "Investing.com Canada", "published_at": "2026-07-10T20:10:48", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing", "summary": "An insider at Bicara Therapeutics (NASDAQ: BCAX) recently sold shares amounting to $833,129, as disclosed in a filing with the SEC. The sale was published on July 10, 2026, at 04:20 pm EDT. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bi", "url": "https://www.marketscreener.com/news/bicara-therapeutics-insider-sold-shares-worth-833-129-according-to-a-recent-sec-filing-ce7f5edfdb8cff26", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T16:20:00", "published_display": "10 Jul 2026 16:20", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics (BCAX) CFO sells 28K shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSWVrUGpxVklJNV84ay14Q2xGSk9aRkpvSldlRjV0MXN6eVJ3Q1JUcjM3Y0xFY1BydXZ5R0syQUo1amtXUWZtbXZoazFyZG9ncHVMcFM2bU5PVWxrNE8yWS1HaVkwSDRhSXdFMDdzWXBqc3EwbHlBWTFDOW9mREZDRWZ2ZXo3YXY2cWhoZlRLdEhqbktobnlDRm96S2NiZXNmQ1h4YkJKamxkREVlSFVTT1lzNGxkcVJL?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bicara Therapeutics Inc. \u2013 NASDAQ:BCAX", "summary": "This article provides financial information for Bicara Therapeutics Inc. (NASDAQ: BCAX), specifically focusing on its price-to-book forward ratio. It's presented within the context of TradingView's financial data platform, indicating key financial metrics for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T09:11:07", "published_display": "09 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Bicara Therapeutics Inc. For: 8 July By Investing.com", "summary": "Investing.com reported on a Form 144 filing by Bicara Therapeutics Inc. for July 8th, indicating an insider transaction or an intent to sell restricted securities. The article, primarily a brief announcement, also includes current stock market data and a disclaimer about trading ", "url": "https://ng.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-8-july-93CH-2591645", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:11:07", "published_display": "08 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sale notice: 28,750 shares disclosed by BCAX (NASDAQ: BCAX)", "summary": "BCAX has filed a Form 144 notice disclosing the planned sale of 28,750 shares. This includes 10,000 shares from an option exercise on May 12, 2024, and 18,750 shares from another exercise on July 8, 2026. The filing also reports two recent sales by Ryan Cohlhepp: 12,500 shares fo", "url": "https://www.stocktitan.net/sec-filings/BCAX/144-bicara-therapeutics-inc-sec-filing-3d32d5f377a4.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:15", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCAX (NASDAQ) affiliate files Rule 144; past sales of 9,200 shares noted", "summary": "An affiliate of Bicara Therapeutics Inc. (BCAX) has filed a Rule 144 notice, indicating proposed sales of 28,000 shares valued at $847,000.00. The filing also detailed two past sales of 9,200 shares each on April 21, 2026, and May 21, 2026, with proceeds of $211,613.80 and $187,8", "url": "https://www.stocktitan.net/sec-filings/BCAX/144-bicara-therapeutics-inc-sec-filing-3d017daa744b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:14", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics\u00a0Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bicara-therapeutics-announces-inducement-grants-123000363.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:30:00+00:00", "published_display": "02 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/645262f3-5acb-3572-a29f-6d292e178204/what-does-the-bicara.html", "source_name": "Motley Fool", "published_at": "2026-06-13T05:21:24+00:00", "published_display": "13 Jun 2026 05:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara (BCAX) Q4 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/b4a29f0b-e79a-3c2f-b18f-5f8e1e14e56e/bicara-%28bcax%29-q4-2025.html", "source_name": "Motley Fool", "published_at": "2026-06-01T16:13:09+00:00", "published_display": "01 Jun 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer", "summary": "", "url": "https://finance.yahoo.com/m/caf6c987-59dc-3d24-bb50-760d13bee685/bicara-therapeutics-asco-data.html", "source_name": "MarketBeat", "published_at": "2026-05-22T15:09:40+00:00", "published_display": "22 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPVDNPN0xESUVqR1Y3bkYxaFJHS3dvaV82aWREUEVYam5MZHpaSFBtbFl2dUt6M1lSd3lwcmZ4YnZsc1hRNjFtQVdfVzEyVk4zeVVtX0JEYWREdFdIZGhrQUgza0NQSHlVWFRWQS1sN0Zya0N4R3VTYXJmLW9Ba25Nd21CVTRTMHdwXzlQSHRSYnZyRlFTNmlXSkVhNnlrOVNzMVZ5ZlJwVQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back", "summary": "", "url": "https://finance.yahoo.com/m/57f8007a-837d-3071-9902-8e6149055817/alumis-stock-is-up-over-300%25..html", "source_name": "Motley Fool", "published_at": "2026-05-15T22:56:41+00:00", "published_display": "15 May 2026 22:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbk14TUdzc3ZZQWtndk44c014UnFlcGJBeHBuUEVqUndvOVloSkkxb1hOQXdrSWZSdGN6MXhzYkYwTFVXVDhZSFNLczVYblBzSjlFNGNNdFZ2Rk9ZV0dHX3NRT3N5YkZ2aFFOSDhKWk10M3EzdDhYd3daVVBoZHhpOVI5RDRLdUVfWk90NFp1MDAwZWE1MEYw?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data", "summary": "", "url": "https://finance.yahoo.com/m/5a253d10-428f-3931-b525-b06d05c87508/bicara-therapeutics-touts.html", "source_name": "MarketBeat", "published_at": "2026-05-14T21:09:08+00:00", "published_display": "14 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Bicara commercial chief lands option on 282,240 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbVZrVHc3VkhGaUh0ckIzZnZ0QTdaQVU2UERQNGVaX2l6aDZDdWlDVzJMcGw3bmt3aUtLbUdpZzhsRzA3R2t1SllJcW1LYWNuRzZKQjgtT3l2a3NmX0VONzNMZVVjbkRValJMTjVyUHlVNnlDWU5hVVV1LUp1Zml3eUhXcnR4TFpCWkhRZW0taHVDTHhJLTlIYUw0ZlV6Yno4WVphVjlrMEs2ankyblZ1NlZGUVpUcXBPMWU5UVZubw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Bicara Therapeutics Q1 2026 sees stock dip after earnings miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQc21RYUE0eVJOZlNHZllBcjhkMmYtMEpGVmF4S0ZGRGNGTXNrZHpLN3diSVVkLXhQSFJ2Rm40RDJEWUkzR1JGOVJmZk9FUmFvYmlPalBfT2pBd0JUcXRxazhqVGUxS3E0NkdpMzdlZkJmOUNRLWYxSHlCTVE3UXF3NHNuRmZaVjRHYi04SkJCRHAxNjhfR3VCRnlwY0tOV3d3ZWFLUFFqamJJellYTW5kcnQzblg5WW1VTVk3MzIxYzdEN292UDFQT0p2OEs2eWJ1cGNKNDRfR1BtV00?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics CFO Hyep sells $211k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNc1NRcDdCX203ZzdfcHZNdTZDbThIM1NmMFpmb2haSTlrRUV5ZDljaGhTT1VxaERFX1pxa09uUHQ1VThLbE9yR1NES25SNnRqX3pRMy1naWlqS19sOEhNNk9ERmtyVWV3cmNwbHJibXFidWtGdHE3TEUyOUlmaDlsbC1pM3UybUNFcFpYaWZQM0lvVkhrN2tzUmhRVS1LSzgwVExyekJ0N3VkNDBxRjVxRW5Ddw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQNDYtQjByZDFJaDlGMlk4bXdmWjBjajdGOXJxcE9hUFRadnVpVmVDSENfRzZFTERwbEsxem9pbEkxR3JLeUxTeFVldlpkUmo0UVdiZ0VkV0ExeXR2Q2FaU2RESjh1OV9mQ1AzcHhyTDJ4bENXMkppd2h5TXNpbzJ6WUswTkpQa1dRVkxwZ0dteHN5MjBnSGZzcHZBN3FlYTlJbnhnQkp4Zw?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQ2lVTENhT2o5bEV3U212MFpUc09VeWFNQmVPRldmakFPS1VyN0tCQ2MxZUQ5dkRfdVdUTUdqWG9QNzNyQ3ZoNGtidFFsTjQybWstUFl4bERWMVlMMkFUcFJsdmJyUWxFank5a2ZGNTZNdWJZR0hSNko4SmQ2UVYtaEVoTmxRWXV6M2V4MzFkd0wySDljLTZDU1VaLS1oekpJRXU1UW1VRWctd21yN3BZZVFTaw?oc=5", "source_name": "qz.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPNEdacW1mbHdoNnFnQkJlVVB5dE5wME41XzRqeWFVLXRkWDluMVpWZTZkbEotUW85U3I5anRZbUNpWUUzeXpVb3ZDMUJKOU1wYVZ2d2xncERLM2JrV1RvTDNNWmt1YmRLNDRTaDB6RWlHWUdMUWotOXpWYWJnbFlIRG9QRjh6ckpnWDlQczVB?oc=5", "source_name": "Market source", "published_at": "2026-03-07T08:00:00+00:00", "published_display": "07 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara raises $172.5M to back planned ficerafusp alfa U.S. launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZUszUEJEV0xGMEQ3bm9QZWN0OUZPcXpUOUNuQXowQS15OGJLTjdBTTA4S2JRRTZwRzltbkZkaFdDYUZLN2JHckFXdF9nV1VIQy1nQkhRZVhGME5MOVd0cDZNUVZyZ08zY3V1WW9NWS14bW93dEMxMF8tQVRwMG1ZNVZuMVBOaWszZHlRZ1MtUG1CdzBiWWVxZXFSSVAyQzZ3NmJtT3RRQkE2a2p0OERMSFVMNHNhR25Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxOSEpBSHhvRjE4T3lLdGlZQzdQZ1NxMkcxSTB4T2tPb2pWdDBpUGc2azBRQmhJc2pFYkFsRlhmcXIyVWlubTNPNmE5X0dyNnVNbkhSMjc1YktBS2pqRjhQblViaXN0Xy1WTzVpV2xCbXFKWlZxYm5rclZ6Q0ZpT1JfSkJNLWl4Z2NWZlRaNkVXeWtsN3ZJM2NOQjA2WFRLdHJKVUo5T1dRdVVCQ0hBbGNuZzVLclpkNTRqM1VZMXZvTWtGQ20xNjY1ZFZnOTZZR0RNc0hZdXdFUlMtUnQwZ0h5dWx1YmNFckxwYXVnNFZKWnUtOG5zandKQ0QyM0VlMFltcFVOc0NhVjQ1YUhV?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug push: Bicara seeks $150M stock sale for launch prep", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWXZGekxrSlRBTXZJa1o5V3dnSTNaVUQ0aHdMclBXTDFwYVpsV2Y0Si01RFBmUzdYSnJvM2NEN2dFWFk4M3QzVzNRUFozaWVYSkVfenNTbi1TMDllTWlvWG1OVDZYNzlwS3k0QlZvQTRUOHE4bW5VZkRPbF9lbWlyMmcwT3NjRGJRSW9Tblo0dzhhV25fMnNrb3N1N0tRTDR2OUF2VFhsUWdEc1A5YmszdXJKNE15aHZzbGxz?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 63, "sentiment_summary": {"positive": 11, "negative": 6, "neutral": 46, "score": 53, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 24.35, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 27.76, "latest_week": "2026-07-17", "one_week_move": -4.0, "four_week_move": 19.5, "twelve_week_move": 22.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.237727, "market_dynamics_buy_signal": false, "relative_strength": 40.897563, "fair_value_gap": 65.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.3382, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, +19.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 9}, {"label": "Investing.com", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "Quartr", "count": 4}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "Motley Fool", "count": 3}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.0% over one week, +19.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Bicara Therapeutics (BCAX) Corporate presentation Summary"}], "updated_at": "2026-07-22T22:35:00.473962+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}